Keyphrases
Recurrent Ovarian Cancer
100%
Multi-institutional
100%
Bevacizumab
100%
Institutional Evaluation
100%
Intestinal Perforation
33%
Tumor Response
22%
Cytotoxic Agents
22%
Chylous Ascites
22%
Hypertension
11%
Response Rate
11%
Overall Response Rate
11%
Retrospective Review
11%
Statistical Analysis
11%
Complete Response
11%
Partial Response
11%
Prior Chemotherapy
11%
Perforation
11%
Stable Disease
11%
Heavily Pretreated Patients
11%
Chemotherapy Regimen
11%
Carbohydrate Antigen 125 (CA125)
11%
Objective Response Rate
11%
Bowel Perforation
11%
Toxicity Response
11%
Relapsed Ovarian Cancer
11%
Medicine and Dentistry
Recurrent Ovarian Cancer
100%
Predictive Factor
100%
Bevacizumab
100%
Gastrointestinal Perforation
33%
Neoplasm
22%
Chylous Ascites
22%
Cytotoxic Agent
22%
Ovarian Cancer
11%
Patient History of Chemotherapy
11%
Intestine Perforation
11%
CA-125
11%
Chemotherapy
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Bevacizumab
100%
Digestive System Perforation
33%
Neoplasm
22%
Chylous Ascites
22%
Cytotoxic Agent
22%
Chemotherapy
11%
Patient History of Chemotherapy
11%
Intestine Perforation
11%
Diseases
11%